SYNTHESIS & CHARACTERIZATION OF NEW MACROMOLECULAR CONTRAST AGENTS

合成

• 批准号: 8363734
• 负责人: Robert Charles Brasch
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363734
• 关键词: Blood; Categories; Characteristics; Chemicals; Contrast Media; Data; Diagnostic; Effectiveness; Electrons; Funding; Grant; Image; MALDI-TOF Mass Spectrometry; Mass Spectrum Analysis; Measurement; Medical Imaging; Microvascular Permeability; Molecular; Molecular Weight; National Center for Research Resources; Organ; Pharmacologic Substance; Principal Investigator; Property; Research; Research Infrastructure; Resources; Role; Source; Structure; Tissues; United States National Institutes of Health; cancer imaging; cost; flexibility; ionization; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Imaging contrast agents (or contrast media) are a category of diagnostic pharmaceuticals for enhancing the image contrast of organs/tissues and for displaying the organ function in medical imaging. Macromolecular contrast agents have found their important role in the characterization of microvascular permeability/leakiness of tumor vessels, due to their blood-pool characteristics. New polyethyleneglycol (PEG)-core dendrimeric contrast agents with well-defined structure, high degree of size homogeneity, synthetic flexibility, and high effectiveness in imaging, have been synthesized. Their average molecular weights (MW) and MW distribution will be obtained from mass spectrometry, which info will be highly valuable for the study of their structure-property relationship and for the guidance of our synthetic optimization. In addition, those new small molecular intermediates, which are attributed to the image contrast, need the structure characterization by mass spectrometry. For different macromolecular derivatives (MW 3,000 - 90,000), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry is used for the measurements of their MW and MW distributions. For small molecular compounds (MW 100 - 2000), electron spray ionization (ESI) mass spectrometry is applicable. Mass spectra data will be correlated with the data from physical and imaging measurements, the relationship among chemical, physical and imaging properties will be sought for this new class of dendrimeric contrast agents. The mass spectra data are highly important and valuable in the synthesis of our new PEG-core dendrimeric contrast agents for cancer imaging.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 成像对比剂（或对比介质）是诊断药物的类别，用于增强器官/组织的图像对比度以及在医学成像中显示器官功能。大分子对比剂已经发现它们在表征微血管渗透性/肿瘤血管泄漏的表征中，由于其血液池特征。已经合成了新的聚乙烯 - 核树状聚合物对比剂，具有明确定义的结构，高度均匀的同质性，合成柔韧性和高效成像的有效性。它们的平均分子量（MW）和MW分布将从质谱中获得，该信息对于研究其结构 - 繁星关系以及我们合成优化的指导将非常有价值。另外，归因于图像对比的那些新的小分子中间体需要通过质谱法进行结构表征。对于不同的大分子衍生物（MW 3,000-90,000），使用基质辅助激光解吸电离飞行时间（MALDI-TOF）质谱法用于测量其MW和MW分布。对于小分子化合物（MW 100-2000），适用电子喷雾电离（ESI）质谱法。质谱数据将与物理和成像测量的数据相关联，这类新型的树突聚合物对比剂将寻求化学，物理和成像特性之间的关系。质谱数据在合成我们新的PEG核树状聚合物对比剂中用于癌症成像的质谱非常重要且有价值。